Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients DOI Open Access
Vincenzo Quagliariello,

Maria Laura Canale,

Irma Bisceglia

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11299 - 11299

Published: Oct. 21, 2024

Cancer patients, especially long cancer survivors, are exposed to several cardio-metabolic diseases, including diabetes, heart failure, and atherosclerosis, which increase their risk of cardiovascular mortality. Therapy with glucagon-like peptide 1 (GLP1) receptor agonists demonstrated beneficial effects, atherosclerosis failure prevention. Cardiovascular outcome trials (CVOTs) suggest that GLP-1 RA could exert cardiorenal benefits systemic anti-inflammatory effects in patients type-2 diabetes through the activation cAMP PI3K/AkT pathways inhibition NLRP-3 MyD88. In this narrative review, we highlight biochemical properties a deep analysis clinical preclinical evidence primary prevention cardiomyopathies. The overall picture review encourages study as potential strategy against atherosclerosis.

Language: Английский

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients DOI Open Access
Vincenzo Quagliariello,

Maria Laura Canale,

Irma Bisceglia

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11299 - 11299

Published: Oct. 21, 2024

Cancer patients, especially long cancer survivors, are exposed to several cardio-metabolic diseases, including diabetes, heart failure, and atherosclerosis, which increase their risk of cardiovascular mortality. Therapy with glucagon-like peptide 1 (GLP1) receptor agonists demonstrated beneficial effects, atherosclerosis failure prevention. Cardiovascular outcome trials (CVOTs) suggest that GLP-1 RA could exert cardiorenal benefits systemic anti-inflammatory effects in patients type-2 diabetes through the activation cAMP PI3K/AkT pathways inhibition NLRP-3 MyD88. In this narrative review, we highlight biochemical properties a deep analysis clinical preclinical evidence primary prevention cardiomyopathies. The overall picture review encourages study as potential strategy against atherosclerosis.

Language: Английский

Citations

1